Rab interacting lysosomal protein like 1Genealiases: GOSPEL · OPDM4 · RLP1
Q-omics provides the consensus-scored RILPL1 profile across patient tissues and cancer cell-line models. RILPL1 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, RILPL1 is differentially expressed in 12, with the highest sampling consensus in THCA. Additionally, RILPL1 RNA expression shows 19,945 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight KIRC, THCA, and ACC as cancer lineages where RILPL1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RILPL1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RILPL1 survival associations across molecular data types. RILPL1 RNA expression shows survival associations in the most cancer types (23), followed by mutation status (5) and mass-spec protein abundance (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RILPL1 RNA expression–survival associations across cancer types. High RILPL1 expression shows unfavorable associations in KIRC, MESO, HNSC, KICH, ACC and BLCA. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for RILPL1 RNA expression.
This table summarizes RILPL1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 5. The strongest signals are observed in THCA for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for RILPL1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RILPL1 shows lower tumor expression in THCA and LUAD and higher tumor expression in KIRP, HNSC, KIRC and LIHC. The THCA box plot shows higher RILPL1 RNA expression in normal versus tumor tissue (log2 FC = −1.664, t-test p < 0.001).
This table shows molecular features associated with RILPL1 in patient tissues and cancer cell lines. In patient samples, RILPL1 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, RILPL1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LIVER, while CRISPR and shRNA rows add functional-dependency signals in URINARY_TRACT and LARGE_INTESTINE.
